A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2022; you can also visit the original URL.
The file type is
We read with interest the article by Sheth et al recently published in JCO Precision Oncology. The authors reported the case of an androgen receptor-positive (AR+) and human epidermal growth factor receptor 2-positive (HER2+) salivary duct carcinoma (SDC) patient responding to alpelisib and bicalutamide 1 after the progression on first-line paclitaxel, carboplatin, and trastuzumab.doi:10.1200/po.21.00262 pmid:34994640 fatcat:hy5onykgzjh57njvplq6qmbyzm